Warning: The NCBI web site requires JavaScript to function. more...
Generate a file for use with external citation management software.
Novartis Institutes for BioMedical Research, Cambridge, Massachusetts 02139, USA. erik.meredith@novartis.com
The synthesis and biological evaluation of potent and selective PKD inhibitors are described herein. The compounds described in the present study selectively inhibit PKD among other putative HDAC kinases. The PKD inhibitors of the present study blunt phosphorylation and subsequent nuclear export of HDAC4/5 in response to diverse agonists. These compounds further establish the central role of PKD as an HDAC4/5 kinase and enhance the current understanding of cardiac myocyte signal transduction. The in vivo efficacy of a representative example compound on heart morphology is reported herein.
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on